Johnson & JohnsonJNJ
▲ PositiveTechnologyrelevance
Caplyta hit its primary endpoint in the pivotal phase III Study 451 for bipolar I mania, supporting a potential label expansion toward $5B peak sales.
Impact on assets 3
Biotech & Genomic Medicine▲ · 3 stocks
Theme Impact 1
Off-coverage companies
Related news
2
Alkermes Reports Positive Phase I Data for ADHD Drug ALKS 7290
Alkermes announced positive top-line data from a phase I proof-of-concept study of its investigational orexin 2 receptor agonist ALKS 7290 in adults with attention-deficit hyperactivity disorder. At day 14, median AISRS total scores fell by 14 points from baseline at the 20-mg dose and 19 points at the 50-mg dose, with improvements also seen on the CGI-S and across the AISRS inattentive and hyperactivity/impulsivity subscales. The treatment was generally well tolerated across all doses, with no serious adverse effects reported, and Alkermes said ALKS 7290 is the first orexin 2 receptor agonist to show clinically meaningful improvements in ADHD symptoms in adults. Enrollment is ongoing in a phase II study of ALKS 7290 in adults with ADHD, with data expected in 2027. Alkermes is also developing alixorexton for narcolepsy type 1 and type 2 in phase III Brilliance studies and for idiopathic hypersomnia in the phase II Vibrance-3 study, with top-line data expected by the end of 2026; the FDA granted alixorexton orphan drug designation for idiopathic hypersomnia in June 2026.
▲
AbbVie Q2 Revenue Rises 10.2% to $16.99 Billion, Beating Estimates
AbbVie reported second-quarter revenues of $16.99 billion, up 10.2% year on year and 1.2% above analysts' consensus expectations, though the quarter was mixed with only a narrow beat of EPS estimates and a slight miss of full-year EPS guidance estimates. The results came as the 11 therapeutics stocks tracked by the report collectively beat consensus revenue estimates by 8% in Q2, with share prices up 24.8% on average since the latest earnings results. Biogen posted the group's best quarter, with revenues of $2.74 billion, up 3.4% year on year and 12.1% above expectations, while Myriad Genetics delivered the weakest performance, reporting revenues of $190.7 million, down 10.5% year on year and 8.2% below expectations, alongside full-year revenue guidance that missed and a significant EPS miss. Gilead Sciences reported revenues of $7.80 billion, up 10.2% year on year and 6.2% above expectations, and Moderna reported revenues of $145 million, up 2.1% year on year and 35.8% above expectations, the biggest analyst estimate beat of the group. AbbVie's stock is up 2.9% since reporting and currently trades at $264.79.
AptarGroup Signs Nose-to-Brain Research Pact With Massachusetts General Hospital
AptarGroup has entered a research agreement with Massachusetts General Hospital to deepen its presence in nose to brain drug delivery, centered on the Stanton Lab's work on neurological disease treatments. The collaboration aims to build a translational research platform combining in vitro, in vivo and computational methods to map how molecules travel from the nasal cavity to the brain, with the resulting methodology expected to integrate Aptar's nasal platforms into early compound evaluation. Cerespray and Neurospray already reflect Aptar's focus on precise deposition in the upper nasal cavity, and embedding those tools into an MGH research framework gives the technology a more formal role in preclinical decision making. The Stanton Lab contributes expertise spanning neurogenetics, omics and cell biology, along with nanotechnology, machine learning and microfluidic systems. AptarGroup shares recently traded at US$123.40, with a 30 day share price return of 8.46% in the red, while the most followed valuation narrative pegs fair value at $155.00, implying the stock is 20.4% undervalued.